Methylation mechanisms in pituitary tumorigenesis

Endocrine-Related Cancer

Volumn 6, Issue 4, 1999, Pages 437-447

  Farrell, W E ^a   Simpson, D J ^a   Frost, S J ^a   Clayton, R N ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; GENE ACTIVATION; GENE DELETION; GENE LOSS; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; HETEROZYGOSITY LOSS; HYPOPHYSIS TUMOR; NONHUMAN; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0033381657     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060437     Document Type: Article

References (58)

1. Antequera F & Bird A 1993a CpG Islands. In DNA Methylation: Molecular Biology and Biological Significance, pp 169-185. Eds JP Jost & HP Saluz. Basel: Birkhauser Verlag.
2. Antequera F & Bird A 1993b Number of CpG islands and genes in human and mouse. Proceedings of the National Academy of Sciences of the USA 90 11995-11999.
3. Arap W, Nishikawa R, Furnari FB, Webster KC & Suhuang HJ 1995 Replacement of the p16/cdkn2 gene suppresses human glioma cell growth. Cancer Research 55 1351-1354.
4. Asa SL, Somers K & Ezzat S 1998 The MEN-1 gene is rarely down-regulated in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 9 3210-3212.
5. Bates AS, Farrell WE, Bicknell EJ, Talbot AJ, Broome JC, Perrett CW, Thakker RV & Clayton RN 1997 Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Journal of Clinical Endocrinology and Metabolism 82 818-824.
6. Baylin SB, Makos M, Wu J, Yen R-WC, de Bustros A, Vertino P & Nelkin BD 1991 Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumour progression. Cancer Cells 3 383-390.
7. Baylin SB, Herman JG, Graff JR, Vertino PM & Issa J-P 1998 Alteration in DNA methylation: a fundamental aspect of neoplasia. In Advances in Cancer Research, pp 141-196. Eds GF Vande Woude & G Kleine. San Diego, CA: Academic Press.
8. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, Mcternan P, Perrett CW, Thakker RV & Clayton RN 1994 Molecular genetic studies of sporadic pituitary tumours. Journal of Clinical Endocrinology and Metabolism 78 387-392.
9. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Cairns P, Polascik TJ & Eby Y 1995 Frequency of homozygous deletion at p16/ CDKN2A in primary human tumours. Nature Genetics 11 210-212.
10. Cameron EE, Bachman KE, Myohanen S, Herman JG & Baylin SB 1999 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics 21 103-107.
11. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL & Marx SJ 1997 Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 404-407.
12. Costello JF, Berger MS, Su Huang H-J & Cavenee WK 1996 Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Research 56 2405-2410.
13. Esteller M, Sanchez-Cespeded M, Rosell R, Sidransky D, Baylin SB & Herman JG 1999 Detection of aberrant promoter hypermethylation of tumour suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Research 59 67-70.
14. European Consortium on MEN1 1997 Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Human Molecular Genetics 6 1177-1183.
15. Farrell WE & Clayton RN 1998 Molecular genetics of pituitary tumours. Trends in Endocrinology and Metabolism 1 20-26.
16. Farrell WE, Simpson DJ, Bicknell EJ, Talbot AJ, Bates AS & Clayton RN 1997 Chromosome 9p deletions in invasive and non-invasive non-functional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Research 57 2703-2709.
17. Farrell WE, Simpson DJ, Bicknell J, Magnay JL, Kyrodimou E, Thakker RV & Clayton RN 1999 Sequence analysis and transcript expression of the men1 gene in sporadic pituitary tumours. British Journal of Cancer 80 p44-p50.
18. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molley PL & Paul CL 1992 A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proceedings of the National Academy of Sciences of the USA 89 1827-1831.
19. 1 arrest in the AtT20 pituitary tumour cell line. Molecular Endocrinology (In Press).
20. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, van Tornout JM & Jones PA 1995 Methylation of the 5′ CpG island of the p16/CDKN2 tumour suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Research 55 4531-4535.
21. Gonzalgo ML, Hayashida T, Bender C, Pao MM, Tsai YC, Gonzales FA, Nguyen HD & Jones PA 1998 The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Research 58 1245-1252.
22. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D & Baylin SB 1995 Inactivation of the CDKN2/ p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Research 55 4525-4530.
23. Herman JG, Jen J, Merlo A & Baylin SB 1996a Hypermethylation-associated inactivation indicates a tumour suppressor role for p151NK4B. Cancer Research 56 722-727.
24. Herman JG, Graff JR, Myohanen S, Nelkin BD & Baylin SB 1996b Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the USA 93 9821-9826.
25. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ & Baylin SB 1997 Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Research 57 837-841.
26. Hsieh CL 1994 Dependence of transcriptional repression on CpG methylalion. Molecular and Cellular Biology 14 5487-5494.
27. Jones PA 1996 DNA methylation errors and cancer. Cancer Research 56 2463-2467.
28. Jones PA 1999 The DNA methylation paradox. Trends in Genetics 15 34-37.
29. Knudson AG Jr 1971 Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the USA 68 820-823.
30. Makos M, Nelkin BD, Lerman Ml, Latif F, Zhar B & Baylin SB 1992 Distinct hypermethylation patterns occur at altered chromosomal loci in human lung and colon cancers. Proceedings of the National Academy of Sciences of the USA 89 1929-1933.
31. Makos M, Nelkin BD, Chazin VR, Cavenee WK, Brodeur GM & Baylin SB 1993a DNA hypermethylation is associated with 17p allelic loss in neural tumours. Cancer Research 53 2715-2718.
32. Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W, Linehan M & Baylin SB 1993b Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Research 53 2719-2722.
33. Melmed S 1994 Pituitary neoplasia. In Multiple Endocrine Neoplasia. Ed RF Gagel. Endocrinology and Metabolism Clinics of North America 23 81-92.
34. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB & Sidransky D 1995 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine 1 686-692.
35. Momparler R & De Vos D 1990 5-Aza-2′-deoxycytidine. In Preclinical and Clinical Studies. Haarlem, The Netherlands: PCH Publications.
36. Oberle IF, Rousseau D, Heitz C, Kretz D, Devys A, Hanauer J, Boue MF, Berheas MF & Mandel JL 1991 Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252 1097-1102.
37. INK4 in human cancer. Proceedings of the National Academy of Sciences of the USA 91 11045-11049.
38. Pei L & Melmed S 1996 Oncogenes and tumour suppressor genes in pituitary tumorigenesis. Frontiers in Hormone Research 20 122-136.
39. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF & Prager D 1995 Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumours: evidence for a chromosome 13 tumour suppressor gene other than RB. Cancer Research 55 1613-1616.
40. Prezant TR, Levine J & Melmed S 1998 Molecular characterization of the Men1 tumour suppressor gene in sporadic pituitary minors. Journal of Clinical Endocrinology and Metabolism 83 1388-1391.
41. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J & Sidransky D 1996 High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Research 56 3630-3633.
42. Sherr CJ 1996 Cancer cell cycles. Science 274 1672-1677.
43. Shimon L & Melmed S 1997 Genetic basis of endocrine disease. Journal of Clinical Endocrinology and Metabolism 82 1675-1681.
44. Simpson DJ, Bicknell JE, McNicol AM, Clayton RN & Farrell WE 1999a Hypermethylation of the p16/CDKN2A/ MTS1 gene and loss of protein expression is associated with non-functional pituitary adenomas but not somatotrophinomas. Genes, Chromosomes and Cancer 24 328-336.
45. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN & Farrell WE 1999b Chromosome 13q deletion mapping in pituitary tumours: infrequent loss of the retino-blastoma susceptibility gene (RBI) locus despite loss of RB1 protein product in somatotrophinomas. Cancer Research 59 1562-1566.
46. ink4. Molecular Carcinogenesis 16 53-60.
47. Szyf M 1996 The DNA methylation machinery as a target for anticancer therapy. Pharmacology and Therapeutics 70 1-37.
48. Tanaka C, KimuraT, Yang P, Moritani M, YamaokaT, Yamada S, Sano T, Yoshimoto K & Itakura M 1998 Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of the MEN1 gene in sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 83 2631-2634.
49. Thakker RV 1993 The molecular genetics of the multiple endocrine neoplasia syndrome. Clinical Endocrinology 38 1-14.
50. Thakker RV, Pook MA, Wooding C, Bocaro M, Scanarini M & Clayton RN 1993 Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations. Journal of Clinical Investigation 91 2815-2821.
51. Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP et al. 1991 Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65 905-914.
52. INK4a gene product in human pituitary tumours. Cancer Research 56 2493-2496.
53. Woloschak M, Yu A & Post KD 1997 Frequent inactivation of the p16 gene in human pituitary tumours by gene methylation. Molecular Carcinogenesis 19 221-224.
54. Wong IHN, Lo YMD, Zhang J, Liew C-T, Ng MHL, Wong N, Lai PBS, Lau WY, Hjelm NM & Johnson PJ 1999 Detection of aberrant p 16 methylation in the plasma and serum of liver cancer patients. Cancer Research 59 71-73.
55. INK4B genes in human pituitary adenomas. European Journal of Endocrinology 136 74-80.
56. INK4a in primary and metastatic breast carcinoma as compared with normal breast tissue. Oncogene 16 2723-2727.
57. Zhuang Z, Ezzat SZ, Vortmeyer AO, Weil R, Oldfield EH, Park WS, Pack S, Huang S, Agarwal SK, Guru SC, Manickam P, Debelenko LV, Kester MB, Olufemi SE, Heppner C, Crabtree JS, Burns AL, Spiegel AM, Marx SJ, Chandrasekharappa SC, Collins FS, Emmert-Buck MR, Liotta LA, Asa SL & Lubensky IA 1997 Mutation of the MEN1 tumour suppressor gene in pituitary tumours. Cancer Research 57 5446-5451.
58. Zingg J-M & Jones PA 1997 Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 18 869-882.